Neurocrine Biosciences Retained Earnings (Accumulated Deficit) 2010-2024 | NBIX

Neurocrine Biosciences retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-0.049B, a 87.45% decline year-over-year.

  • Neurocrine Biosciences retained earnings (accumulated deficit) for 2023 were $-0.157B, a 61.38% decline from 2022.
  • Neurocrine Biosciences retained earnings (accumulated deficit) for 2022 were $-0.407B, a 36.02% decline from 2021.
  • Neurocrine Biosciences retained earnings (accumulated deficit) for 2021 were $-0.636B, a 12.35% decline from 2020.

Neurocrine Biosciences Retained Earnings (Accumulated Deficit) 2010-2024 | NBIX

  • Neurocrine Biosciences retained earnings (accumulated deficit) for 2023 were $-0.157B, a 61.38% decline from 2022.
  • Neurocrine Biosciences retained earnings (accumulated deficit) for 2022 were $-0.407B, a 36.02% decline from 2021.
  • Neurocrine Biosciences retained earnings (accumulated deficit) for 2021 were $-0.636B, a 12.35% decline from 2020.